AMLX Amylyx Pharmaceuticals, Inc. - Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · amylyx.com

27.79USD0.00%Mkt Cap: 3.55B $P/E: —Today

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provid…

Industry Peers

Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$57.06BUSD

TEVA

Teva Pharmaceutical Industries Limited Ordinary Shares

$46.10BUSDP/E 65.9

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Zoetis Inc. Class A Common Stock

$28.80BUSDP/E 11.4

UTHR

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB (publ)

$14.14BUSDP/E 110.6

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated Common Stock

$11.06BUSD

RDY

Dr. Reddy's Laboratories Ltd Common Stock

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc. Class A Common Stock

$6.77BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

INDV

Indivior Pharmaceuticals, Inc. - Common Stock

$4.21BUSDP/E 12.8

Key Statistics

Company

Market Cap3.55B USD

Enterprise Value2.85B USD

Revenue (TTM)—

Gross Profit0 USD

Net Income (TTM)-144.74M USD

Revenue/Share—

Last Price27.79 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees136

CountryUS

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-24.07

PEG—

EV/EBITDA-17.63

EV/Revenue—

P/S—

P/B12.94

EPS (TTM)-1.41

EPS (Forward)-1.15

52W Range

10.8356% of range41.13

52W High41.13 USD

52W Low10.83 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-47.41%

ROA-43.51%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-123.34M USD

CapEx (TTM)138.00K USD

FCF Margin—

FCF Yield-2.18%

Net Debt-245.50M USD

Net Debt/EBITDA1.52

Balance Sheet

Debt/Equity0.02

Current Ratio12.12

Quick Ratio11.88

Book Value/Sh2.15 USD

Cash/Share2.25 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.2 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)42.36 USD

Upside (mean)+52.4%

Target Range20.00 USD – 57.00 USD

20.00+52.4% to mean57.00

# Analysts11

Ownership

Shares Out.125.51M

Float97.25M

Insiders7.18%

Institutions92.40%

Short Interest

Short Ratio3.7d

Short % Float13.48%

Short % Out.10.77%

Shares Short13.51M

Short (prev mo.)13.43M

Technical

SMA 5029.33 (-5.3%)

SMA 20018.52 (+50.1%)

Beta-0.12

S&P 52W Chg14.58%

Avg Vol (30d)1.83M

Avg Vol (10d)1.27M

Technical Indicators

RSI (14)41.5

MACD0.1040

MACD Signal1.0399

MACD Hist.-0.9359

BB Upper35.81 USD

BB Middle31.57 USD

BB Lower27.34 USD

BB Width26.83%

ATR (14)1.669 USD

Vol Ratio (20d)0.64x